PDRN electrophoresis purity detection is a critical quality control technique used to verify the molecular integrity, fragment size distribution, and purity of polydeoxyribonucleotide (PDRN) products intended for pharmaceutical, aesthetic, and regenerative medicine applications. By leveraging agarose gel electrophoresis, polyacrylamide gel electrophoresis, and densitometric analysis, manufacturers can confirm that PDRN raw materials and finished injectables meet stringent regulatory requirements. This comprehensive technical guide covers the testing principles, sample types, analytical procedures, acceptance criteria, and practical applications of PDRN purity evaluation.
Technical Overview
Polydeoxyribonucleotide (PDRN) is a linear, double-stranded DNA polymer fraction derived primarily from salmon milt (sperm) through controlled extraction, purification, and controlled depolymerization. The therapeutically active fraction typically consists of DNA fragments ranging from approximately 50 to 2,000 base pairs, corresponding to molecular weights between roughly 50 kDa and 1,500 kDa. Because the pharmacological activity, safety profile, and regulatory compliance of PDRN products depend directly on fragment size distribution and molecular homogeneity, electrophoresis purity detection serves as one of the most important analytical tests in the PDRN manufacturing workflow.
Electrophoresis purity detection separates DNA molecules according to their size and conformation under an electric field through a porous gel matrix. When a PDRN sample is analyzed alongside a DNA molecular weight marker, the resulting banding or smearing pattern reveals the fragment size distribution, the degree of degradation, and the presence of contaminating species such as residual RNA, proteins, or undigested genomic DNA. A high-purity PDRN preparation typically presents as a discrete, homogeneous band or a well-defined smear within the target molecular weight range, while impurities appear as additional bands, trailing smears, or fluorescence at the dye front.
- Size-based separation of PDRN fragments using agarose or polyacrylamide gel matrices
- Visualization with intercalating fluorescent dyes such as ethidium bromide, SYBR Safe, or GelRed
- Semi-quantitative purity assessment through densitometric scanning of the gel image
- Detection of RNA, protein, and high-molecular-weight genomic DNA contamination
- Verification of batch-to-batch consistency and process control validation
Testing Samples
PDRN Raw Materials (Sodium Polydeoxyribonucleotide Powder)
Bulk sodium PDRN active pharmaceutical ingredient (API) is the most common sample type submitted for electrophoresis purity testing. The powder is dissolved in nuclease-free buffer or sterile injection-grade water at a defined concentration, typically 1 to 5 mg/mL, before loading onto the gel. Testing at the raw material stage confirms that the depolymerization and purification processes have produced fragments within the specified size window before the material is formulated into finished products.
PDRN Injectable Solutions
Finished PDRN injectable products, such as those used in skin booster and regenerative aesthetic treatments at concentrations of 2.07% to 3%, are tested to verify that the final formulation has not degraded during sterilization, filling, or storage. Direct loading or buffer exchange may be required depending on the excipient composition of the formulation.
Manufacturing Intermediates
In-process samples collected after extraction, enzymatic depolymerization, ultrafiltration, or ion-exchange chromatography steps are analyzed to monitor process consistency and to establish in-process control limits. Electrophoresis at intermediate stages helps identify at which point size drift or contamination occurs, enabling rapid corrective action.
Cosmetic-Grade and Research-Grade PDRN
PDRN intended for topical cosmetic formulations or laboratory research is tested with the same electrophoretic principles, although acceptance criteria may differ from pharmaceutical-grade specifications depending on the intended use and applicable regulatory framework.
Testing Items
Electrophoresis purity detection for PDRN encompasses several measurable attributes that together define the quality of the sample. The specific items evaluated include:
- Molecular weight distribution: confirmation that fragments fall within the specified range, commonly 50 to 2,000 base pairs or a customer-defined window
- Purity percentage: the proportion of total detected nucleic acid signal located within the target size range, with typical acceptance criteria of ≥95% or ≥98%
- RNA residue detection: residual RNA appears as a diffuse, low-molecular-weight smear near the dye front and indicates incomplete removal during purification
- Protein contamination: residual proteins can alter migration behavior or appear as non-nucleic acid signals when assessed with complementary staining
- High-molecular-weight genomic DNA: undegraded DNA remains near the well and signals over-digested or under-digested depolymerization
- Smear homogeneity: uniform intensity distribution across the target range indicates controlled depolymerization and consistent manufacturing
Testing Methods
Agarose Gel Electrophoresis
Agarose gel electrophoresis is the primary method for PDRN purity detection. Gel concentrations between 1.0% and 2.0% provide effective resolution across the typical PDRN fragment range. The dissolved sample is mixed with loading dye containing glycerol and a tracking dye, loaded alongside a DNA ladder such as a 100 bp or 1 kb molecular weight marker, and run in TAE or TBE buffer at a constant voltage of 80 to 120 V. After electrophoresis, the gel is stained and visualized under UV or blue-light transillumination, and the image is documented for interpretation.
Polyacrylamide Gel Electrophoresis (PAGE)
For PDRN fractions containing smaller fragments below approximately 100 base pairs, or when higher resolution is required to distinguish closely spaced bands, native or denaturing polyacrylamide gels at concentrations of 6% to 12% offer superior resolving power compared with agarose.
Capillary Electrophoresis
Capillary electrophoresis with laser-induced fluorescence detection provides quantitative, automated fragment analysis with high sensitivity and reproducibility. Increasingly used for release testing of injectable PDRN products, this method generates precise electropherograms from which molecular weight distribution and purity percentage are calculated against certified size standards.
Densitometric Analysis and Interpretation
Gel images are analyzed using image analysis software to generate lane profiles and integrate peak areas. The purity percentage is calculated as the area of signal within the target size window divided by the total signal in the lane. Results are reported with the observed size range, purity percentage, a visual record of the gel image, and an explicit statement of pass or fail against the agreed specification.
Applications
Electrophoresis purity detection supports the entire PDRN product lifecycle across multiple industries and regulatory contexts:
- Batch release testing of PDRN API and injectable finished products for pharmaceutical markets in South Korea, Europe, and emerging regulatory jurisdictions
- Quality control of aesthetic injectables, including skin boosters and mesotherapy solutions containing PDRN
- Stability studies evaluating molecular degradation under accelerated and long-term storage conditions
- Process validation and comparability studies following manufacturing changes or scale-up
- Regulatory dossier support with objective purity data for registration submissions
- Supplier qualification and incoming material inspection programs
- Academic and industrial research requiring verified PDRN fragment integrity
FAQ
What purity level is generally required for PDRN products? Most pharmaceutical and injectable-grade specifications require that at least 95% to 98% of the nucleic acid signal fall within the defined molecular weight range, with the exact threshold established in the product specification agreed between manufacturer and client.
How much sample is needed for testing? Typically 10 to 50 mg of PDRN powder or 0.5 to 1 mL of injectable solution is sufficient for a complete electrophoretic purity assessment, including repeat analysis if required.
Which method should be chosen, agarose gel electrophoresis or capillary electrophoresis? Agarose gel electrophoresis is cost-effective and widely accepted for routine screening, while capillary electrophoresis delivers superior quantitative precision and is preferred for formal batch release of regulated injectable products.
What factors can cause out-of-specification results? Common causes include enzymatic over-digestion or under-digestion during depolymerization, nuclease contamination leading to fragmentation, thermal degradation during sterilization, and incomplete removal of RNA or protein impurities during purification.
How are results reported? A complete test report includes the gel image or electropherogram, observed molecular weight range, calculated purity percentage, comparison against the DNA size standard, and a conformity statement relative to the specified acceptance criteria.
Can degraded PDRN batches be reprocessed? Depending on the degradation profile, some batches can be rescued through additional fractionation or purification steps, and electrophoresis testing is repeated afterward to verify compliance before release.